Coronary Calcium Score: Who It Helps, and Who Should Skip It

The offer usually arrives at the end of a visit: a short CT scan of the heart, no contrast, no preparation, that returns a single number — the coronary calcium score, known in Israel simply as a “calcium score.” It is offered mainly in middle age, to men typically earlier than to women, when the picture is borderline, and it is usually paid for privately. Coverage through supplementary insurance (bituach mashlim) varies between the health funds (kupot holim) and between plans, and it is worth checking in advance. The question people bring to us is almost always the same one: is it worth it.

The answer barely depends on the test. It depends almost entirely on where you stand before it. This is an excellent test for one person and an almost entirely redundant one for another, and the two of them may be sitting in the same waiting room with the same lipid panel. The purpose of this article is to let you say which group you belong to.

What a coronary calcium score actually measures

The scan itself is brief: you lie on the CT table, ECG stickers synchronise the acquisition with your heartbeat, and you hold your breath a few times for a few seconds each. No contrast, no cannula, no fasting, no recovery time. The software identifies calcium deposits in the coronary arteries, multiplies the area of each deposit by a density factor, and sums everything into one number — the Agatston score.

It matters to understand what is being counted. The calcium is not the plaque. It is the mineral component of plaque that has already healed and stabilised — a scar, not an active lesion. So the score does not measure the dangerous plaque itself; it counts the traces that plaque has left behind, and serves as a proxy for the total atherosclerotic burden accumulated over a lifetime. It is a good proxy — in large cohort studies it is among the strongest predictors of cardiovascular events, beyond the conventional risk factors. It remains, all the same, a proxy.

The number, the percentile, and why the percentile leads the conversation

The report comes back in two parts: an absolute score, and beside it a percentile adjusted for age and sex. The difference between them is exactly the difference between “how much” and “how early.” A score of 80 in a sixty-seven-year-old man is an entirely routine finding — a relatively low percentile, roughly what would be expected. The same score of 80 in a forty-seven-year-old man is a different story altogether: it places him well above his peers, and it says the process in him is moving faster than usual.

In practice, the treatment thresholds are drawn from the absolute score — the accepted guidelines speak to a score of zero, to the mild range, and to the range beyond which lipid-lowering therapy is almost always indicated. But the conversation in the room turns on the percentile, and rightly so: it is what translates an abstract number into a statement about pace, and pace is what a fifty-year-old actually wants to know. The conventional ranges are simple enough:

• Zero. No calcium detected. In middle age this is a finding with real weight — more on that below.
• 1–99. Mild burden. Usually tips the scale toward treatment, particularly when the percentile is high for age.
• 100–399. Moderate burden. In most guidelines this is already a category in which lipid-lowering therapy is recommended, not merely considered.
• 400 and above. Extensive burden. A patient in this range is managed, in practice, at high risk — close to the way someone with known coronary disease is managed, and with no symptoms at all.

The test is not there to tell you whether you have atherosclerosis. It is there to break a tie between two treatment options that are otherwise evenly balanced. If the decision is already made, in either direction, the number will be interesting rather than useful.

Zero in middle age is among the most reassuring answers in preventive medicine

This is where the test does its best work. In a properly selected middle-aged adult, a score of zero predicts an exceptionally low event rate over the following years — low enough to justify deferring drug therapy in someone whose calculated risk was borderline to begin with, and revisiting the question in a few years. Very few tests in preventive medicine can take a decision off the table with that degree of confidence.

Two caveats travel with that answer. First, zero is not a certificate of immunity but a period of quiet: calcium may appear later, which is why the question gets asked again — usually after several years, depending on the starting level of risk. Second, zero does not cancel risk factors the scan cannot see. Someone with elevated Lp(a), a family history of an early event, diabetes or a current smoking habit keeps that risk even when the scan is clean — and those are precisely the groups the guidelines carve out when they permit deferring treatment on the strength of a zero.

A high score changes the plan the same day

The other end of the scale is no less decisive. A person who arrived assuming they were low risk, with reasonable blood pressure, no smoking history and an LDL-C that is “a little high,” and who comes back with a score in the hundreds, is no longer a candidate for a discussion about prevention. They have documented coronary atherosclerosis, and the conversation moves at once from “whether to start” to “how far to lower.”

What changes, concretely: the ApoB and LDL-C targets tighten to the levels guidelines reserve for high risk; blood pressure and glycaemic control are managed to stricter targets; and the aspirin question, no longer a routine recommendation for primary prevention in most people, returns as a case-by-case discussion. Lifestyle change, which until yesterday was a general recommendation, acquires a target and a timetable. This is precisely the situation in which one test moves a decade of decisions.

When the test contributes nothing

And here the logic inverts. Where a decision already exists, the test is almost always redundant:

• Someone already on a statin and well managed. A high score will not change treatment that is already being given. What it will generate is anxiety, and sometimes a cascade of work-up nobody planned.
• Someone who has firmly decided against drug therapy under any circumstances. A test whose answer will change nothing is not a clinical test; it is curiosity with an invoice.
• Someone whose risk is already clearly high. Diabetes, known coronary disease, or familial hypercholesterolaemia — the guidelines mandate aggressive treatment regardless, and a score of zero will not rescind it.
• Someone with symptoms. Chest pain on exertion or new shortness of breath is not a prevention question. It calls for a cardiology work-up, not a calcium score.

That leaves one well-defined group: an asymptomatic person at intermediate calculated risk who is genuinely undecided about starting lipid-lowering therapy. For that person, few tests in preventive medicine contribute more to the decision. For everyone else, less so.

The limitations, without softening them

Calcium is the healed form of plaque. Soft, lipid-rich, non-calcified plaque is the biologically active kind and the kind that tends to rupture — and it does not register on the scan at all. A score of zero therefore does not rule out plaque, only calcified plaque. This is also why the test performs poorly at younger ages: in a thirty-nine-year-old, zero is the expected result anyway, and so it carries almost no information.

There is radiation. The dose is low — on the order of the natural background radiation a person absorbs over a period of months, and lower still on newer scanners. It is not zero, and it is a genuine consideration when the question is repeat scanning in a younger person.

The score can rise precisely when treatment is working. A recognised and confusing phenomenon: plaque that stabilises tends to calcify, so a calcium score that climbs in a patient on a statin is not necessarily a sign of failure. For that reason the test is a poor tool for monitoring treatment response, contrary to what intuition suggests.

And not every finding stays within the borders of the heart. The scan also images part of the lungs and mediastinum, and occasionally turns up an incidental finding that requires work-up — usually benign, but not always. That is a standing cost of any broad imaging, familiar from the debate around whole-body MRI.

Coronary calcium, CIMT and CTA: three different questions

The common confusion is that these are three tiers of the same test. They are not. Carotid ultrasound images the artery wall itself and the non-calcified plaque within it, with no radiation — which makes it informative precisely where calcium is weak, at younger ages. Coronary calcium quantifies accumulated burden in the coronary arteries themselves, and in older adults it is generally the stronger predictor of the two. CT angiography sees both kinds of plaque and the stenoses, at the price of contrast and a higher radiation dose, and its place is in the work-up of symptoms or of questions the score alone did not settle.

How to know whether you are the person this test was designed for

Before booking the scan, it is worth answering three questions, in this order. First, what is your calculated ten-year risk, and who actually calculated it — a number, not a feeling. Second, are you genuinely undecided about treatment, or has the decision already been made and you are looking for its endorsement. Third, what would you do with each of the two possible answers. If the answer to the third question is the same either way, you have just saved yourself a scan.

And it is worth making sure the basic picture is complete first. ApoB, a once-in-a-lifetime Lp(a), properly measured blood pressure and an accurate family history — all of these are cheaper, more accessible, and frequently settle the decision without any imaging. That is also why a standard executive screening does not usually include this test, and should not: it is not a screening test for everyone, but a tie-breaking instrument for the person standing at exactly the right point.

If you are at that point, the test is available in Israel and it is quick; it does require a referral, and the coverage and the cost are worth clarifying in advance. If you are not, the money and the time will find better use elsewhere. In either case, the decision should be made with someone who will read the result in the context of the rest of the clinical picture, not as a number that arrives in the post. You can book a call and work out which group you belong to before you book the scan.